

The logo for DiaSorin, featuring the company name in white serif font on a dark blue square background.

DIASORIN S.P.A., THE ORDINARY SHAREHOLDERS' MEETING APPROVES THE 2007 STATUTORY FINANCIAL STATEMENTS AND THE DIVIDEND DISTRIBUTION

Saluggia, April 24, 2008 – The Ordinary Shareholders' Meeting, convened under the chairmanship of Gustavo Denegri, was attended by shareholders representing 71.972% of the Company' s share capital, who reviewed and approved the statutory financial statements at December 31, 2007 and the dividend distribution motion.

Diasorin S.p.A. ended 2007 with revenues of 117.1 million euros, or 8.9% more than in 2006, and a net profit of 10.0 million euros, compared with 10.4 million euros in 2006. It is worth noting than in the year ended December 31, 2007, the Group' s Parent Company incurred nonrecurring expenses of 4.5 million euros in connection with the listing of its shares on the Milan Stock Exchange, while the 2006 bottom line included extraordinary income of 1.9 million euros from a grant received in connection with research projects eligible pursuant to Law No. 346/1998.

The Shareholders' Meeting also approved a motion to distribute a dividend of 0.10 euros per share, with record date of July 14, 2008 and payment date of July 17, 2008.

About Diasorin

Diasorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The Diasorin Group comprises 12 companies based in Europe, the United States, Central and South America and Asia. It has more than 900 employees, including over 80 research and development specialists, and operates three manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany) and Stillwater (USA). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing..

Contacts:

Investor Relations Officer

Laura Villa

Diasorin S.p.A.

laura.villa@diasorin.it

+39 0161487532

+39 348 15 11 542

Press Office

Carolina Mailander

c.mailander@mailander.it

+39 335 655 56 51

Bruno Caprioli

caprioli@mailander.it

+39 335 590 14 02